The pharmacies in the Facility Inspections Warning Letters section are FDA-registered 503B outsourcing facilities. They operate under stricter oversight, must follow current good manufacturing process (cGMP), and use ingredients sourced from FDA-registered suppliers
Effect of the Glucagon-Like Peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER
Review scores vary, with established manufacturers often scoring higher (e.g., Foshan Saigao Toys at 4.9)
But here is the thing: the moment that phrase entered the cultural lexicon thanks to the rise of GLP-1 medications, every single one of my clients struggling with binge eating and disordered eating knew EXACTLY what it meant
At a glance Retatrutide is an investigational weekly injection from Eli Lilly, not yet licensed in the UK It targets three hormone receptors at once GLP-1, GIP and glucagon earning it the nickname "triple G" It reduces appetite, improves blood sugar, and appears to nudge resting energy expenditure upwards Phase 2 trial participants lost an average of around 24% of body weight over 48 weeks at the top dose Side effects mirror existing GLP-1 medications: nausea, mild gut symptoms, reduced appetite Expected UK approval is 18-24 months away pending Phase 3 results and MHRA review The basics: what retatrutide is Retatrutide is an investigational weekly injection being developed by Eli Lilly for weight loss and related metabolic conditions
